Clinical trials
Allogeneic Stem Cell Transplantation clinical trials
Below are recruiting allogeneic stem cell transplantation clinical trials, each written for real people, not researchers. We’re tracking 377 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04022239RecruitingPhase 1/Phase 2
Bendamustine to prevent transplant immune complications
This early-phase study tests whether giving the drug bendamustine (with or without another chemo drug) can lower the risk of graft-versus-host disease (GVHD) after a stem cell transplant. GVHD is an immune reaction where the donor’s cells attack your body. If it works and is safe, it could improve outcomes after transplant.
Houston, TexasAges 18–70 - NCT03980769RecruitingPhase 2
Stem cell transplant trial for non-cancer blood disorders
This Phase 2 study tests a specific chemotherapy combination (treosulfan, fludarabine, and thiotepa) before an unrelated or matched donor stem cell transplant. It may help people with certain non-cancer blood and immune disorders by trying to reset the immune system using donor stem cells.
Seattle, WashingtonAges Up to 50 years - NCT03964506RecruitingEarly Phase 1
Hyperbaric oxygen plus donor stem cell transplant for blood cancers
This early-phase trial studies whether breathing pure oxygen in a pressurized chamber, along with a donor stem cell transplant, can improve outcomes for certain blood cancers. It may help by supporting the body during transplant and recovery, but it is still being tested for safety and effectiveness.
Rochester, New YorkAges 18–75 - NCT03719105RecruitingEarly Phase 1
Chemo plus immunotherapy with donor stem cell transplant for NK lymphoma
This early-phase study tests a combination treatment—chemo, immunotherapy, and a donor stem cell transplant—for certain aggressive NK/T-cell lymphomas. It may help patients who have advanced-stage disease by trying to improve long-term control of the cancer.
Birmingham, AlabamaAges 1–31 - NCT03850418RecruitingPhase 2
Azacitidine for blood chimerism changes after transplant
This Phase 2 study tests whether azacitidine can improve outcomes when donor blood “chimerism” starts dropping after an allogeneic stem cell transplant. It’s for people with AML, MDS, MPN, or CMML who are experiencing early warning signs in their blood counts after transplant but without clear relapse in the bone marrow.
Detroit, MichiganAges 18–75 - NCT03673748RecruitingPhase 2
Mesenchymal stem cell treatment for lupus kidney inflammation
This trial tests whether donated (allogeneic) stem cells can improve lupus nephritis, a kidney complication of lupus. It is for adults whose lupus kidney disease has not responded well to standard treatments or has come back, and it requires signs of active disease.
Valladolid, ValladolidAges 18 years+ - NCT03533816RecruitingPhase 1
Gamma delta T-cell infusion after stem cell transplant
This early-phase study tests giving a special immune-cell treatment after an allogeneic (donor) stem cell transplant, plus a medication given after transplant to help the new immune system work better. It may help prevent or treat cancer returning after transplant.
Westwood, KansasAges 18–65 - NCT03670966RecruitingPhase 1/Phase 2
Targeted iodine therapy, then donor transplant for hard leukemias
This trial tests an antibody-linked radioactive iodine treatment, followed by a donor stem cell transplant, for people with relapsed or refractory high-risk acute leukemia or certain MDS. It may help patients by targeting leukemia cells and then using a new immune system to control the disease.
Seattle, WashingtonAges 18–75 - NCT03665675RecruitingEarly Phase 1
Immune cell treatment to control CMV or adenovirus after transplant
This early-phase study tests donor immune cells made to recognize CMV (a virus) or adenovirus, given to help control virus reactivation after a solid organ or bone marrow transplant. It may help reduce ongoing or worsening viral infection when standard antiviral medicines are hard to tolerate or not working well.
Columbus, OhioAges 1–85 - NCT03707262RecruitingPhase 1/Phase 2
Brother or sister donor transplant using kidney and stem cells
This study tests a combined approach for kidney transplant patients: standard living-donor kidney transplant plus an added “stem cell” component taken from the same sibling donor. It aims to improve transplant outcomes by trying to better control the immune response and reduce complications.
Los Angeles, CaliforniaAges 18 years+ - NCT03394365RecruitingPhase 3
Tabelecleucel for EBV-related lymphoma after transplant treatment failure
This trial tests tabelecleucel, an immune therapy, for people whose EBV-associated post-transplant lymphoproliferative disease (PTLD) did not respond to rituximab and/or chemotherapy. It may help your immune system better control EBV-driven lymphoma after a transplant.
Duarte, CaliforniaAges Any age - NCT03354728RecruitingPhase 1/Phase 2
Vaccine trial for children with CMV after stem cell transplant
This trial studies a vaccine designed to help the body fight cytomegalovirus (CMV) in children who test positive for CMV and are about to receive a donor stem cell transplant. If it works, it may reduce CMV-related illness during recovery after transplant.
Duarte, CaliforniaAges 1–21 - NCT03378102RecruitingEarly Phase 1
AdV-targeted T cells for adenovirus after bone marrow transplant
This trial tests a custom immune cell treatment (T cells made to recognize adenovirus) for people whose adenovirus infection is not improving or who cannot tolerate standard antiviral medicines after a bone marrow transplant. It aims to help your body control the virus and prevent organ complications.
Cleveland, OhioAges 3 months+ - NCT03279094RecruitingPhase 1
Testing a half-matched bone marrow transplant for sickle cell
This early-phase study tests whether a “half-matched” donor bone marrow transplant, with special medicines to calm the immune system before transplant, can improve outcomes for people with sickle cell disease. It may help high-risk patients who have frequent complications and don’t have a fully matched donor.
Duarte, CaliforniaAges 1–30 - NCT03128034RecruitingPhase 1/Phase 2
Astatine-211 treatment before stem cell transplant for high-risk blood cancers
This trial tests a targeted radiation drug (Astatine-211) given before a donor stem cell transplant for people with high-risk leukemia or certain bone-marrow cancers. The goal is to better control the cancer before the transplant.
Seattle, WashingtonAges 18–75 - NCT02677064Recruiting
Study on barriers to stem cell transplant for acute leukemia
This study looks at what makes it hard for people with acute leukemia or related blood cancers to get a stem cell transplant. It aims to find ways to help more people get this treatment.
Hartford, ConnecticutAges 18–80 - NCT01861106RecruitingPhase 2
Bone marrow transplant for GATA2 mutations
This trial tests a bone marrow transplant (called allogeneic hematopoietic stem cell transplant) as a treatment for people with GATA2 mutations or MonoMAC. The goal is to replace faulty immune cells with healthy donor cells, which may reduce infections and improve immune function.
Bethesda, MarylandAges 6–70 - NCT01949129RecruitingPhase 2/Phase 3
Stem cell transplant trial for children with certain leukemia types
This trial tests whether children and teens with a specific type of acute lymphoblastic leukemia (ALL) do well after getting donor stem cells (an allogeneic transplant). It may help by using a standardized transplant approach for people in complete remission before the transplant.
Buenos AiresAges 1 month–18 years - NCT01666080Recruiting
Second bone marrow transplant with gentler chemotherapy
This trial studies a “reduced intensity” second transplant using donated blood-forming cells, for people whose first transplant did not fully and reliably restart blood production. It aims to improve donor blood cell growth while using a less harsh conditioning approach.
Minneapolis, MinnesotaAges Up to 55 years - NCT02048332RecruitingPhase 1/Phase 2
Donor immune cells for preventing infections after stem cell transplant
This trial studies donor-made immune cells (T-cells) given after a stem cell transplant to help your body fight infections. It aims to test how safe the treatment is and whether it supports the immune system in the months after transplant.
Akron, OhioAges 4 weeks+ - NCT01174108RecruitingPhase 2
Stem cell transplant with donor T-cells for severe bone marrow failure
This Phase 2 study tests a specific type of donor stem cell transplant for severe bone marrow failure conditions, aiming to improve cure rates while reducing transplant risks. It includes people with diseases like severe aplastic anemia and certain bone marrow disorders, especially when standard transplant plans feel too risky.
Baltimore, MarylandAges 4–80 - NCT07438067RecruitingPhase 1
EBV-targeted cell therapy after stem cell transplant
This trial tests a special immune cell therapy (EBV-AST) for people who have high levels of Epstein-Barr virus (EBV) in their blood after a stem cell transplant. The goal is to see if it can safely control the virus and prevent related complications.
BeijingAges 18–75 - NCT06845592Recruiting
Stronger radiation and cell therapy before stem cell transplant for high-risk leukemia
This trial tests a special transplant approach for people with high-risk acute leukemia. It uses a stronger dose of radiation before transplant, followed by an infusion of immune cells (regulatory and conventional T cells) to help the transplant work better and fight the leukemia.
Perugia, PGAges 18–65 - NCT06365671RecruitingPhase 2
CAR-T therapy after stem cell transplant for high-risk B-cell lymphoma
This trial tests a combination treatment: a stem cell transplant followed by CAR-T cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. It is for those with high-risk features like large tumors or certain genetic changes.
ShanghaiAges 18 years+
Hear when a new Allogeneic Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for allogeneic stem cell transplantation?
- Yes. Clin2 currently lists 377 recruiting allogeneic stem cell transplantation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a allogeneic stem cell transplantation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a allogeneic stem cell transplantation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Allogeneic Hematopoietic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Hematopoietic Stem Cell Transplantation
- Stem Cell Transplantation
- Hematopoetic Stem Cell Transplantation
- Haploidentical Hematopoietic Stem Cell Transplantation
- Autologous Hematopoietic Stem Cell Transplantation
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.